COMPASS Pathways plc (CMPS) stock
CMPSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.12−0.18 (-1.94%)
Close on Nov 12, 2026Market cap $1.26BP/E –Yield –
COMPASS Pathways r&d expenses
Research and development expenses are spending on new products and technology.
COMPASS Pathways's R&D Expenses for the twelve months ending Jun 30, 2026 was $112.89M, down 10.6% year over year. For fiscal 2025 it was $118.44M, down 0.5% from the year before. The highest annual figure on record is $119.04M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $118.44M | -0.5% |
| FY2024 | Dec 31, 2024 | $119.04M | +36.0% |
| FY2023 | Dec 31, 2023 | $87.52M | +34.5% |
| FY2022 | Dec 31, 2022 | $65.05M | +47.8% |
| FY2021 | Dec 31, 2021 | $44.03M | +88.4% |
| FY2020 | Dec 31, 2020 | $23.37M | +86.0% |
| FY2019 | Dec 31, 2019 | $12.56M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.18M | -3.8% |
| Q1 FY2026 | Mar 31, 2026 | $26.48M | -14.2% |
| Q4 FY2025 | Dec 31, 2025 | $29.91M | -7.0% |
| Q3 FY2025 | Sep 30, 2025 | $27.33M | -17.0% |
| Q2 FY2025 | Jun 30, 2025 | $30.33M | +4.3% |
| Q1 FY2025 | Mar 31, 2025 | $30.88M | +24.0% |
| Q4 FY2024 | Dec 31, 2024 | $32.14M | +18.4% |
| Q3 FY2024 | Sep 30, 2024 | $32.93M | +53.0% |
| Q2 FY2024 | Jun 30, 2024 | $29.07M | +46.7% |
| Q1 FY2024 | Mar 31, 2024 | $24.90M | +30.8% |
| Q4 FY2023 | Dec 31, 2023 | $27.14M | +37.1% |
| Q3 FY2023 | Sep 30, 2023 | $21.53M | +54.0% |
| Q2 FY2023 | Jun 30, 2023 | $19.82M | +24.5% |
| Q1 FY2023 | Mar 31, 2023 | $19.04M | +23.9% |
| Q4 FY2022 | Dec 31, 2022 | $19.79M | +45.6% |
| Q3 FY2022 | Sep 30, 2022 | $13.98M | +14.6% |
| Q2 FY2022 | Jun 30, 2022 | $15.92M | +40.2% |
| Q1 FY2022 | Mar 31, 2022 | $15.36M | +123.2% |
| Q4 FY2021 | Dec 31, 2021 | $13.59M | +199.1% |
| Q3 FY2021 | Sep 30, 2021 | $12.20M | +77.4% |
| Q2 FY2021 | Jun 30, 2021 | $11.35M | +68.8% |
| Q1 FY2021 | Mar 31, 2021 | $6.88M | – |
| Q4 FY2020 | Dec 31, 2020 | $4.54M | – |
| Q3 FY2020 | Sep 30, 2020 | $6.88M | – |
| Q2 FY2020 | Jun 30, 2020 | $6.72M | – |
See a number that looks wrong?